Study S002546

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Oral Administration of HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

ClinicalTrials.gov record

Registration

Registration: NCT06520540
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 72
Start: 2024-07-28
Primary completion: 2024-11-30
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Glucagon-Like Peptide-1 Receptor Agonists
Interventions: DRUG:HDM1002 100 mg QD 12weeks; DRUG:HDM1002 200 mg QD 12weeks; DRUG:HDM1002 400 mg QD 12weeks，Q 2W for titration; DRUG:HDM1002 400 mg QD 12weeks，Q 3W for titration; DEVICE:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

TEAEs, SAEs, AEs leading to withdrawal, and AEs leading to death, AEs of special interest [Baseline, Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.